title: Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy.
abstract: In this secondary analysis of a dose-titration study of patients with hypertension uncontrolled on prior monotherapy, blacks (n=234) and non-blacks (n=765) were switched to amlodipine (AML)/olmesartan medoxomil (OM) 5/20 mg, with uptitration every 4 weeks to AML/OM 5/40 mg and then AML/OM 10/40 mg to achieve a seated cuff blood pressure (SeBP) of <120/70 mm Hg. Hydrochlorothiazide 12.5 and 25 mg could be added if SeBP was ≥125/75 mm Hg. The cumulative proportions of patients achieving systolic SeBP <140 mm Hg (<130 mm Hg if diabetic) at 12 weeks were 71.6% for blacks and 77.2% for non-blacks. Mean SeBP change from baseline in blacks (mean baseline BP: 153.0/93.7 mm Hg) ranged from -11.7/-6.1 mm Hg for AML/OM 5/20 mg to -23.6/-12.9 mm Hg for AML/OM 10/40 mg +hydrochlorothiazide 25 mg (all P<.0001). Antihypertensive efficacy was maintained throughout the 24-hour dosing interval. An AML/OM-based regimen was effective in blacks with hypertension uncontrolled on prior monotherapy.
authors.affiliation: UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8586, USA. shawna.nesbitt@utsouthwestern.edu
authors.forename: Shawna
authors.initials: S
authors.lastname: Nesbitt
authors.forename: Ali
authors.initials: A
authors.lastname: Shojaee
authors.forename: Jen-Fue
authors.initials: JF
authors.lastname: Maa
mesh_terms: D000328:Adult; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D016903:Drug Monitoring; D057915:Drug Substitution; D005006:Ethnicity; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000208:ethnology; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D007093:Imidazoles; D013777:Tetrazoles; D017311:Amlodipine; D000068557:Olmesartan Medoxomil
references.citation: J Am Coll Cardiol. 2011 May 17;57(20):2037-114
references.pmid: 21524875
references.citation: Ethn Dis. 2003 Summer;13(2 Suppl 2):S48-52
references.pmid: 13677414
references.citation: J Hypertens. 2004 Jun;22(6):1113-8
references.pmid: 15167445
references.citation: Circulation. 2005 Feb 8;111(5):697-716
references.pmid: 15699287
references.citation: J Hypertens. 2011 Jul;29(7):1243-52
references.pmid: 21540748
references.citation: J Clin Hypertens (Greenwich). 2005 Apr;7(4 Suppl 1):9-14
references.pmid: 15858397
references.citation: Postgrad Med. 2010 Jan;122(1):118-24
references.pmid: 20107295
references.citation: J Am Soc Hypertens. 2011 Jul-Aug;5(4):239-48
references.pmid: 21524638
references.citation: Ethn Dis. 2011 Spring;21(2):129-34
references.pmid: 21749014
references.citation: Arch Intern Med. 2003 Mar 10;163(5):525-41
references.pmid: 12622600
references.citation: J Hypertens. 2007 Jun;25(6):1105-87
references.pmid: 17563527
references.citation: Natl Health Stat Report. 2011 Mar 25;(35):1-22, 24
references.pmid: 21485611
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Feb 4;60(4):103-8
references.pmid: 21293325
references.citation: Ther Adv Cardiovasc Dis. 2010 Apr;4(2):119-27
references.pmid: 20042448
references.citation: JAMA. 2003 May 21;289(19):2560-72
references.pmid: 12748199
references.citation: Circulation. 2009 Jan 27;119(3):e21-181
references.pmid: 19075105
references.citation: Hypertension. 2010 Nov;56(5):780-800
references.pmid: 20921433
references.citation: Crit Pathw Cardiol. 2007 Jun;6(2):67-71
references.pmid: 17667868
references.citation: J Clin Hypertens (Greenwich). 2011 Jun;13(6):404-12
references.pmid: 21649839